Trillium Therapeutics (Trillium Therapeutics) Interest Expense : $0.00 Mil (TTM As of Sep. 2021)

Trillium Therapeutics Interest Expense Chart

Trillium Therapeutics Annual Data
	Trend	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20
Interest Expense		Get a 7-Day Free Trial					-0.06	-0.05	-0.04	-0.18	-

Trillium Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Interest Expense	Get a 7-Day Free Trial															-0.04	-	-	-	-

Trillium Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trillium Therapeutics  (NAS:TRIL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Trillium Therapeutics's Interest Expense for the three months ended in Sep. 2021 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2021 was $-19.45 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2021 was $0.34 Mil.

Trillium Therapeutics's Interest Coverage for the quarter that ended in Sep. 2021 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. Trillium Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Trillium Therapeutics (Trillium Therapeutics) Business Description